Anti-sRANKL antibody (ab62516)
Key features and details
- Rabbit polyclonal to sRANKL
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Overview
-
Product name
Anti-sRANKL antibody
See all sRANKL primary antibodies -
Description
Rabbit polyclonal to sRANKL -
Host species
Rabbit -
Specificity
IHC-P has not been validated for use with mouse and rat.
-
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide (Human) of 14 amino acids from near the centre of sRANKL
-
Positive control
- WB: A431, K562 and HeLa cell lysates. Mouse kidney and skin tissue lysates. Rat liver tissue lysate. IHC-P: Human liver tissue.
-
General notes
This antibody will recognize both the soluble form and the uncleaved transmembrane form of RANK-L.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
pH: 7.2
Preservative: 0.02% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab62516 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
Use a concentration of 0.25 - 0.5 µg/ml. Detects a band of approximately 30 kDa (predicted molecular weight: 35 kDa).
|
IHC-P | (2) |
Use a concentration of 5 µg/ml.
Only validated for human samples. |
Notes |
---|
WB
Use a concentration of 0.25 - 0.5 µg/ml. Detects a band of approximately 30 kDa (predicted molecular weight: 35 kDa). |
IHC-P
Use a concentration of 5 µg/ml. Only validated for human samples. |
Target
-
Function
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. -
Tissue specificity
Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. -
Involvement in disease
Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. -
Sequence similarities
Belongs to the tumor necrosis factor family. -
Post-translational
modificationsThe soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17. -
Cellular localization
Cytoplasm; Secreted and Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 8600 Human
- Entrez Gene: 21943 Mouse
- Entrez Gene: 117516 Rat
- Omim: 602642 Human
- SwissProt: O14788 Human
- SwissProt: O35235 Mouse
- SwissProt: Q9ESE2 Rat
- Unigene: 333791 Human
see all -
Alternative names
- CD254 antibody
- hRANKL2 antibody
- ODF antibody
see all
Images
-
All lanes : Anti-sRANKL antibody (ab62516) at 1 µg/ml
Lane 1 : A431 cell lysate
Lane 2 : HeLa cell lysate
Lane 3 : K562 (Human chronic myelogenous leukemia cell line from bone marrow) cell lysate
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat anti-rabbit IgG HRP conjugate at 1/10000 dilution
Predicted band size: 35 kDa
Observed band size: 36 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST.
-
All lanes : Anti-sRANKL antibody (ab62516) at 2 µg/ml
Lane 1 : Mouse kidney tissue lysate
Lane 2 : Mouse skin tissue lysate
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat anti-rabbit IgG HRP conjugate at 1/10000 dilution
Predicted band size: 35 kDa
Observed band size: 36 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST.
-
Lane 1 : Anti-sRANKL antibody (ab62516) at 0.25 µg/ml
Lane 2 : Anti-sRANKL antibody (ab62516) at 0.5 µg/ml
All lanes : Rat liver tissue lysate
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat anti-rabbit IgG HRP conjugate at 1/10000 dilution
Predicted band size: 35 kDa
Observed band size: 30 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST.
-
Immunohistochemical analysis of paraffin-embedded human liver tissue using ab62516 at 5µg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1h at RT. Antigen retrieval was by heat mediation with a citrate buffer (pH 6.0). Samples were incubated with primary antibody overnight at 4°C. Goat anti-rabbit IgG H&L (HRP) at 1/250 dilution was used as a secondary. Counter stained with Hematoxylin.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (19)
ab62516 has been referenced in 19 publications.
- Feng SY et al. Increased joint loading induces subchondral bone loss of the temporomandibular joint via the RANTES-CCRs-Akt2 axis. JCI Insight 7:N/A (2022). PubMed: 36173680
- Gama A et al. Origins of Alterations to Rankl Null Mutant Mouse Dental Root Development. Int J Mol Sci 21:N/A (2020). PubMed: 32209985
- Shu Q et al. Mechanisms by which electroacupuncture-mediated histone acetylation mitigates bone loss in rats with ovariectomy-induced osteoporosis. Mol Med Rep 22:3453-3463 (2020). PubMed: 32945471
- Xu W et al. Bajitianwan attenuates D-galactose-induced memory impairment and bone loss through suppression of oxidative stress in aging rat model. J Ethnopharmacol 261:112992 (2020). PubMed: 32590113
- Ge N et al. Orthodontic treatment induces Th17/Treg cells to regulate tooth movement in rats with periodontitis. Iran J Basic Med Sci 23:1315-1322 (2020). PubMed: 33149864